Patent Assignment
Reel/Frame 023373/0684
Security Agreement
Recorded: 2009-10-15
Pages: 87
Assignor
META PROTEOMICS, LLC
Executed: 2009-10-14
Assignee
BANK OF AMERICA, N.A.
333 S. HOPE ST., SUITE 1300, MAIL CODE: CA9-193-13-01, LOS ANGELES, CALIFORNIA, 90071
Covered Properties
(60)
Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2
Combinations of Sesquiterpene Lactones and Ditepene Triepoxide Lactones for Synergistic Inhibition of Cyclooxygenase-2
Combinations of Diterpene Triepoxide Lactones and Ditepene Lactones or Triterpenes for Synergistic Inhibition of Cyclooxygenase-2
Novel Anti-Inflammatory Cyclooxygenase Inhibitors
Combinations of Psyllium and Chitosan for Synergistic Adsorption of Triglyceride
Oral Composition with Insulin-Like Activities and Methods of Use
Curcuminoid Compositions Exhibiting Synergistic Inhibition of the Expression and/or Activity of Cyclooxygenase-2
Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2
Synergistic Compositions That Treat or Inhibit Pathological Conditions Associated with Inflammatory Response
Modulation of inflammation by hops fractions and derivatives
Application:
10/464,834 →
Publication:
US 2004/0115290
Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2
Compositions that treat or inhibit pathological conditions associated with inflammatory response
Anti-Inflammatory Pharmaceutical Compositions for Reducing Inflammation and the Treatment or Prevention of Gastric Toxicity
Synergistic Anti-Inflammatory Pharmaceutical Compositions and Methods of Use
Application:
10/590,301 →
Publication:
US 2007/0249728
Synergistic Anti-Inflammatory Pharmaceutical Compositions and Related Methods Using Curcuminoids or Methylxanthines
Compositions That Treat or Inhibit Pathological Conditions Associated with Inflammatory Response
Synergistic anti-inflammatory pharmaceutical compositions and methods of use
Application:
10/789,814 →
Publication:
US 2005/0192356
Synergistic Anti-Inflammatory Pharmaceutical Compositions and Related Methods Using Curcuminoids or Methylxanthines
Inhibition of Cox-2 and/or 5-Lox Activity by Fractions Isolated or Derived from Hops
Curcuminoid Compositions Exhibiting Synergistic Inhibition of the Expression and/or Activity of Cyclooxygenase-2
Treatment Modalities for Autoimmune Diseases
Modulation of inflammation by hops fractions and derivatives
Application:
11/344,552 →
Publication:
US 2006/0127511
Modulation of Inflammation by Hops Fractions and Derivatives
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
Application:
11/344,555 →
Publication:
US 2006/0127513
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
Application:
11/344,556 →
Publication:
US 2006/0127514
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
Application:
11/344,557 →
Publication:
US 2006/0127515
Modulation of Inflammation by Hops Fractions and Derivatives
Synergistic Compositions That Treat or Inhibit Pathological Conditions Associated with Inflammatory Response
Anti-Inflammatory Pharmaceutical Compositions for Reducing Inflammation and the Treatment or Prevention of Gastric Toxicity
Anti-Inflammatory Pharmaceutical Compositions for Reducing Inflammation and the Treatment of Prevention of Gastric Toxicity
Compositions That Treat or Inhibit Pathological Conditions Associated with Inflammatory Response
Modulation of Inflammation by Hops Fractions and Derivatives
Protein Kinase Modulation by Hops and Acacia Products
Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2
Application:
11/623,400 →
Publication:
US 2007/0172532
Anti-Inflammatory Botanical Products for the Treatment of Metabolic Syndrome and Diabetes
Protein kinase modulation by hops and Acacia products
Application:
11/636,867 →
Publication:
US 2007/0154576
Treatment Modalities for Autoimmune Diseases
Compositions Exhibiting Inhibition Of Cyclooxygenase-2
Application:
11/667,614 →
Publication:
US 2009/0274778
Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2
Application:
11/667,615 →
Publication:
US 2009/0263522
Curcuminoid Compositions Exhibiting Synergistic Inhibition of the Expression and/or Activity of Cyclooxygenase-2
Compositions That Treat or Inhibit Pathological Conditions Associated with Inflammatory Response
Xanthohumol and Tetrahydro-Isoalpha Acid Based Protein Kinase Modulation Cancer Treatment
Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
Application:
11/820,600 →
Publication:
US 2008/0031982
Isoalpha acid based protein kinase modulation cancer treatment
Application:
11/820,607 →
Publication:
US 2008/0051466
Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
Application:
11/820,608 →
Publication:
US 2008/0033057
Acacia based protein kinase modulation cancer treatment
Application:
11/820,621 →
Publication:
US 2008/0031893
Reduced isoalpha acid based protein kinase modulation
Application:
11/820,653 →
Publication:
US 2008/0026088
Beta acid based protein kinase modulation cancer treatment
Application:
11/820,755 →
Publication:
US 2008/0031894
Protein kinase modulation by hops and acacia products
Application:
11/823,934 →
Publication:
US 2008/0031986
Methods and Compositions for Heavy Metal Detoxification
Methods and Compositions for Promoting Bone and Joint Health
Protein Kinase Modulation by Hops and Acacia Products
Application:
12/063,039 →
Publication:
US 2008/0248131
Substituted 1,3-Cyclopentadione Multi-Target Protein Kinase Modulators of Cancer, Angiogenesis and the Inflammatory Pathways Associated Therewith
Application:
12/331,887 →
Publication:
US 2010/0137449
Substituted 1, 3-Cyclopentadione Attenuated Endothelial Inflammation and Endothelial-Monocyte Interactions
Application:
12/417,205 →
Publication:
US 2010/0222262
Substituted 1,3-Cyclopentadione Attenuated Endothelial Inflammation and Endothelial - Monocyte Interactions
Application:
61/041,631 →
Method for the Purification of Iso-Alpha Acid Congeners and Reduced Iso-Alpha Acid Congener from a Complex Mixture Using Countercurrent Separation
Application:
61/121,419 →
Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
Application:
61/197,185 →
Phytochemical compositions and methods for activating AMP-kinase
Application:
61/198,387 →
Substituted 1,3-Cyclopentadione and Acacia Nilotica Extract Based Compositions and Methods For Weight Management
Application:
61/234,081 →
Substituted 1,3-Cyclopentadione Compositions and Methods For Weight Management
Application:
61/234,091 →
Related Assignments
(11)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 21, 2007
From: BABISH, JOHN G.; TRIPP, MATTHEW L.; BLAND, JEFFREY S.
To: METAPROTEOMICS, LLC
Reel/Frame 019860/0909 →
Release of Security Interest
Oct 26, 2009
From: COMERICA BANK
To: METAGENICS, INC.; METAGENICS FAR EAST, INC.; META PROTEOMICS, LLC
Reel/Frame 023419/0486 →
Release of Security Interest
Oct 26, 2009
From: COMERICA BANK
To: METAGENICS, INC.; METAGENICS FAR EAST, INC.; META PROTEOMICS, LLC
Reel/Frame 023424/0038 →
Release of Security Interest
Oct 26, 2009
From: COMERICA BANK
To: METAGENICS, INC.; METAGENICS FAR EAST, INC.; META PROTEOMICS, LLC
Reel/Frame 023423/0951 →
Release of Security Interest
Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
Security Interest
Nov 1, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP., AS COLLATERAL AGENT
Reel/Frame 057981/0156 →
Security Interest
Nov 4, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP. (AS COLLATERAL AGENT)
Reel/Frame 058015/0602 →
Assignment of Assignor's Interest
Feb 16, 2024
From: METAPROTEOMICS, LLC
To: METAGENICS LLC
Reel/Frame 066485/0677 →
Security Interest
Dec 22, 2025
From: METAGENICS LLC
To: WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT
Reel/Frame 073293/0381 →
Termination and Release of Patent Security Agreement - Reel/Frame 058015/0602
Dec 23, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074050/0670 →
Termination and Release of Patent Security Agreement - Reel/Frame 057981/0156
Dec 24, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074057/0392 →